<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03594149</url>
  </required_header>
  <id_info>
    <org_study_id>CHB 17.01</org_study_id>
    <nct_id>NCT03594149</nct_id>
  </id_info>
  <brief_title>Efficiency of Antibacterial Prophylaxis in Azacitidine Treated Patients</brief_title>
  <acronym>AZABAC</acronym>
  <official_title>Efficiency of Antibacterial Prophylaxis (Levofloxacin) in Azacitidine Treated Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Henri Becquerel</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Henri Becquerel</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Infections are a major life-threatening complication in patients with myelodysplastic
      syndrome (MDS) or acute myeloid leukaemia (AML). Currently there is no guidelines about
      antibacterial prophylaxis to prevent infections in patients with myelodysplastic syndrome or
      acute myeloid leukaemia. The investigators will conduct a randomized prospective study to
      evaluate the benefit of prophylactic antibacterial by levofloxacin on febrile episode in
      Azacytidine treated patients (MDS and AML).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a randomized prospective study with 2 arms to evaluate the efficacy of Levofloxacin
      prophylaxis in Azacytidine treated patients (MDS and AML) Levofloxacin will be given 500mg/d
      p.o. for the first three cycles of Azacytidine in patients randomized in arm antibacterial
      prophylaxis. In control arm patients will not received levofloxacin.

      The expected duration of subject participation is one year after randomization.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 18, 2018</start_date>
  <completion_date type="Anticipated">July 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 11, 2021</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Febrile episode occurrence</measure>
    <time_frame>3 cycles of 28 days</time_frame>
    <description>Febrile episode occurrence during the3 first cycles of azacytidine requiring hospitalization and introduction of an antibiotic (with or without levofloxacin discontinuation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>one-year overall survival rate</measure>
    <time_frame>one year</time_frame>
    <description>overall survival at one year in both two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infectious agents documented in each arm</measure>
    <time_frame>one year</time_frame>
    <description>index of infectious agents in both two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>infectious events rate</measure>
    <time_frame>one year</time_frame>
    <description>number of infectious events in both two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>apparition of multi-drug resistant bacteria</measure>
    <time_frame>one year</time_frame>
    <description>index of multi-drug resistant bacteria in both two arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>duration of hospitalization</measure>
    <time_frame>one year</time_frame>
    <description>number of days of hospitalization and number of days of antibiotic or antifungal treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>carbapenem and glycopeptide consumption in both two arms</measure>
    <time_frame>3 years</time_frame>
    <description>consumption of carbapenem and glycopeptide during inclusion period and comparison with the 3 previous years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>death causes</measure>
    <time_frame>one year</time_frame>
    <description>index of death causes in each arms</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>toxicity profile (adverse event)</measure>
    <time_frame>one year</time_frame>
    <description>toxicity will be established with description of adverse event in both two arms</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">150</enrollment>
  <condition>Myelodysplastic Syndromes</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <arm_group>
    <arm_group_label>antibacterial prophylaxis</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Levofloxacin 500 mg/d p.o. during the first 3 cycles of azacytidine</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>No levofloxacin will be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Levofloxacin</intervention_name>
    <description>Levofloxacin 500 mg/d p.o.</description>
    <arm_group_label>antibacterial prophylaxis</arm_group_label>
    <other_name>LVF</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age superior to 18 years old

          -  SMD or AML treated with azacytidine (not previously treated)

          -  Life expectancy more than 3 months

          -  Performance status inferior to 3

          -  signed inform consent

        Exclusion Criteria:

          -  allergy to quinolone

          -  previous event of tendopathy due to quinolone

          -  previous epileptic event

          -  systemic antibacterial prophylaxis the month before enrolment

          -  HIV positive

          -  bacterious infection of indetermined fever

          -  participation to an investigational drug trial

          -  Abnormalities in hepatic assessment

          -  QTc superior to 450 ms

          -  Pregnant or lactating women

          -  Myasthenia

          -  G6PD deficient

          -  severe and uncontrolled diabetes

          -  patient not able to understand trial
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stamatoullas-Bastard Aspasia, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Henri Becquerel</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Richard Doriane, phD</last_name>
    <phone>+33232082985</phone>
    <email>doriane.richard@chb.unicancer.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>CHU Amiens</name>
      <address>
        <city>Amiens</city>
        <zip>80000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gruson Berangere, Md</last_name>
    </contact>
    <investigator>
      <last_name>Gruson Berangere, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHU Caen</name>
      <address>
        <city>Caen</city>
        <zip>14033</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Cheze Stephane, Md</last_name>
    </contact>
    <investigator>
      <last_name>Cheze Stephane, Md</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>CHRU Lille</name>
      <address>
        <city>Lille</city>
        <zip>59037</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Berthon Celine, Md</last_name>
    </contact>
    <investigator>
      <last_name>Berthon CÃ©line, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Centre Henri Becquerel</name>
      <address>
        <city>Rouen</city>
        <zip>76000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Richard Doriane, PhD</last_name>
      <phone>+33232082985</phone>
      <email>doriane.richard@chb.unicancer.fr</email>
    </contact>
    <investigator>
      <last_name>Stamatoullas-Bastard Aspasia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>July 2018</verification_date>
  <study_first_submitted>July 10, 2018</study_first_submitted>
  <study_first_submitted_qc>July 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">July 20, 2018</study_first_posted>
  <last_update_submitted>July 20, 2018</last_update_submitted>
  <last_update_submitted_qc>July 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">July 24, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>levofloxacin, antibacterial prophylaxis, febrile episode</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Levofloxacin</mesh_term>
    <mesh_term>Ofloxacin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

